Zynerba Pharmaceuticals Inc (ZYNE) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $22. H.C. Wainwright advised their investors in a research report released on Oct 7, 2016.
In a different news, on Aug 17, 2016, Suzanne M. Hanlon (Sec, General Counsel & VP HR) purchased 3,000 shares at $17.92 per share price. According to the SEC, on Aug 12, 2015, Thomas L Harrison (director) purchased 12,500 shares at $14.00 per share price.
Zynerba Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates including ZYN002 and ZYN001 which represent cannabinoid therapeutics for several indications including refractory epilepsy Fragile X syndrome (FXS) osteoarthritis (OA) fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies ZYN002’s permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.